The Outcome of Chronic Kidney Disease Patients With Obstructive Sleep Apnea Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorNanfang Hospital, Southern Medical University
About this trial
Obstructive sleep apnea (OSA) is highly prevalent in chronic kidney disease (CKD) patients and strongly linked to obesity, metabolic syndrome, and type 2 diabetes. Besides elevating cardiovascular disease risk, OSA may worsen renal function and diminish quality of life, making its understanding critical for CKD patient health.
This study will establish a large, long-term cohort of non-dialysis CKD patients to identify OSA risk factors, explore OSA's association with adverse renal outcomes, and determine OSA prevalence and epidemiological characteristics within the CKD population. The findings will provide a scientific foundation for early OSA identification, diagnosis, and intervention in CKD patients.
Eligibility criteria
Qualifiers
Voluntarily sign the informed consent form;
Aged ≥ 18 years and < 75 years;
Patients with CKD stages 3-4, with an eGFR of 15-60 ml/min/1.73m² calculated using the CKD-EPI formula for at least 3 months.
Disqualifiers
Patients receiving oxygen therapy or continuous positive airway pressure (CPAP) treatment;
Patients with other sleep disorders, including restless legs syndrome, periodic limb movement disorder, etc.;
Patients with other severe comorbidities: Severe heart failure (NYHA class III or IV); Myocardial infarction, unstable angina, or stroke within the past 3 months; Severe arrhythmias requiring medication or device therapy; Respiratory diseases, including COPD, asthma, thoracic deformities, etc.; Neurological disorders, including myasthenia gravis, Parkinson's disease, Alzheimer's disease, etc.; Active liver disease or severe hepatic insufficiency; Psychiatric conditions, including depression, anxiety disorders, etc.; History of malignancy within the past 5 years (except cured basal cell carcinoma); Uncontrolled hyperthyroidism;
Patients who underwent surgery or had acute infections within the past 3 months;
Trial design
Treatments tested in this trial
- No intervention
Treatment groups
356 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov